All In Biotech

Drug Trial Radar · NCT05253833

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

A Phase 2, Randomized, Open-Label, Allopurinol-Controlled, Multicenter Study With Two Optional Extensions to Evaluate the Safety and Efficacy of AR882 Alone or in Combination With Allopurinol in Tophaceous Gout Patients

Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Aug 12, 2022

Primary completion

Aug 13, 2024

Study completion Oct 28, 2024

Sponsor

Lead sponsor
Arthrosi TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.

Conditions

  • Gout
  • Arthritis, Gouty
  • Hyperuricemia
  • Gout Chronic

Interventions

  • AR882 Dose 1Drug

    Solid Oral Capsule

  • AR882 Dose 2Drug

    Solid Oral Capsule

  • Allopurinol TabletDrug

    Solid tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum urate (uric acid) (sUA) level < 5 mg/dL at month 3Time frame: 12 weeks

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Arthrosi Investigative Site (410)

    Birmingham, Alabama

  • Arthrosi Investigative Site (403)

    Phoenix, Arizona

  • Arthrosi Investigative Site (416)

    Sun City, Arizona

  • Arthrosi Investigative Site (417)

    Tucson, Arizona

  • Arthrosi Investigative Site (402)

    Tampa, Florida

  • Arthrosi Investigative Site (404)

    Boise, Idaho

  • Arthrosi Investigative Site (409)

    Ann Arbor, Michigan

  • Arthrosi Investigative Site (406)

    Greensboro, North Carolina

  • Arthrosi Investigative Site (408)

    Myrtle Beach, South Carolina

  • Arthrosi Investigative Site (401)

    Dallas, Texas

  • Arthrosi Investigative Site (201)

    Auckland, New Zealand

  • Arthrosi Investigative Site (303)

    Taichung, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.